Haemostasis stops bleeding at the site of vascular injury and maintains the integrity of blood
vessels through clot formation. This regulated physiological process consists of complex …

Thrombosis with associated inflammation (thromboinflammation) occurs commonly in a
broad range of human disorders. It is well recognized clinically in the context of superficial …

Factor XI (FXI) is the zymogen of a plasma protease, factor XIa (FXIa), that contributes to
thrombin generation during blood coagulation by proteolytic activation of several …

Factor XI deficiency is associated with a bleeding diathesis, but factor XII deficiency is not,
indicating that, in normal hemostasis, factor XI must be activated in vivo by a protease other …

Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in
Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous …

Introduction: Inherited fXI deficiency has been an enigma since its discovery in 1953. The
variable and relatively mild symptoms in patients with even the most severe form of the …

The most commonly used anticoagulants produce therapeutic antithrombotic effects either
by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of …

Abstract Background Milvexian (BMS‐986177/JNJ‐70033093) is an orally bioavailable
factor XIa (FXIa) inhibitor currently in phase 2 clinical trials. Objectives To evaluate in vitro …

Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by
activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to …

Coagulation activation is a prominent feature of severe acute respiratory syndrome
coronavirus 2 (COVID-19) infection. Activation of the contact system and intrinsic pathway …